Japan Tobacco Reports Strong Financial Results for 2022

Nov.02.2022
Japan Tobacco Reports Strong Financial Results for 2022
Japan Tobacco reports strong growth in revenue, profits driven by solid pricing in tobacco business and success of Ploom X.

Tobacco Company "Riyan" has reported that its revenue for the first nine months of 2022 was 2 trillion Japanese yen ($13.5 billion USD), which represents a year-over-year growth of 13.7% compared to 2021.


The core income, calculated at fixed exchange rates, grew by 4.1% to reach 1.77 trillion yen. Operating profit adjusted for fixed exchange rates increased by 6.5% to reach 78.4 billion yen. Annual report data showed that adjusted operating profit increased by 17.5% to reach 6.378 trillion yen. Operating profit increased by 20.5% to reach 5.793 trillion yen, while profit rose by 19.2% to reach 4.038 trillion yen.


In a statement, President and CEO of Japan Tobacco Group, Masamichi Terabatake, stated that the company has demonstrated strong performance over nine months, primarily driven by stable pricing in its tobacco business. He also expressed encouragement towards the sales of Ploom X and its performance on the stock market in Japan. The company has launched Ploom X in London, and plans to accelerate its international release from 2023.


Terabatake expressed high expectations for the recently announced collaboration with Altria Group to market and commercialize heated tobacco products in the United States. He stated, "I firmly believe that this collaboration will increase the likelihood of harm reduction for adult consumers and drive value for both JT and Altria.


Terabatake stated, "Due to positive commercial momentum and a favorable currency trend for the Japanese yen, we have revised our full-year 2022 forecast upwards. According to the revised guidelines, we are pleased to announce our plan to increase our annual dividend guidance from 38 Japanese yen to 188 Japanese yen.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is intended solely for industry-related research and communication purposes.


Due to limitations in the level of translation proficiency, the translated article may not fully express the original text. Please refer to the original article for accuracy.


2FIRSTS holds the same views and positions as the Chinese government on all matters related to domestic affairs, as well as those that involve Hong Kong, Macau, Taiwan, and foreign countries.


The ownership of the compilation of information belongs to the original media and author. If there is any copyright infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal is among the countries opposing the UK Tobacco and Vapes Bill, which would ban tobacco sales to people born on or after Jan. 1, 2009. According to the report, Portugal, Croatia, the Czech Republic, Greece, Italy, Slovakia and Romania have submitted reasoned opinions and formal observations to Brussels, arguing that the bill breaches post-Brexit arrangements including the Windsor Framework.
Apr.24 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
From May 8 to 10, 2026, Mylor (Booth E70) will exhibit at The Vaper Expo UK, where it will showcase its systematic experience design solutions for e-liquids. At present, the e-liquid market commonly faces a challenge: many products have “no obvious shortcomings, but lack memorable features.” In response, Mylor has proposed refined solutions across multiple dimensions, including device-adaptive sweetness, progressive cooling sensation, fruit-oriented sourness, and segmented nicotine experience.
May.08
Bangladesh Industry Association Calls for Regulated Framework Instead of Vape Ban
Bangladesh Industry Association Calls for Regulated Framework Instead of Vape Ban
Bangladesh Electronic Nicotine Delivery Systems Traders Association said at a press conference on April 9 that use of e-cigarette products under regulated policy frameworks has produced positive public health outcomes globally.
Apr.10 by 2FIRSTS.ai
South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea’s Ministry of Food and Drug Safety said on April 17 that it has additionally designated the International Characterization Research Institute as a tobacco harmful components testing body under the Act on the Management of Tobacco Harmfulness. The institute has research experience in analyzing harmful components in liquid e-cigarettes and has obtained recognition for tobacco-sector ISO 17025 requirements.
Apr.17 by 2FIRSTS.ai